1. Home
  2. BLTE vs AMRX Comparison

BLTE vs AMRX Comparison

Compare BLTE & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLTE
  • AMRX
  • Stock Information
  • Founded
  • BLTE 2018
  • AMRX 2002
  • Country
  • BLTE United States
  • AMRX United States
  • Employees
  • BLTE N/A
  • AMRX N/A
  • Industry
  • BLTE Biotechnology: Pharmaceutical Preparations
  • AMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLTE Health Care
  • AMRX Health Care
  • Exchange
  • BLTE Nasdaq
  • AMRX Nasdaq
  • Market Cap
  • BLTE 4.1B
  • AMRX 3.7B
  • IPO Year
  • BLTE 2022
  • AMRX N/A
  • Fundamental
  • Price
  • BLTE $124.75
  • AMRX $11.59
  • Analyst Decision
  • BLTE Strong Buy
  • AMRX Buy
  • Analyst Count
  • BLTE 5
  • AMRX 3
  • Target Price
  • BLTE $105.00
  • AMRX $12.67
  • AVG Volume (30 Days)
  • BLTE 96.5K
  • AMRX 1.8M
  • Earning Date
  • BLTE 11-10-2025
  • AMRX 10-30-2025
  • Dividend Yield
  • BLTE N/A
  • AMRX N/A
  • EPS Growth
  • BLTE N/A
  • AMRX N/A
  • EPS
  • BLTE N/A
  • AMRX 0.02
  • Revenue
  • BLTE N/A
  • AMRX $2,934,959,000.00
  • Revenue This Year
  • BLTE N/A
  • AMRX $10.20
  • Revenue Next Year
  • BLTE N/A
  • AMRX $6.95
  • P/E Ratio
  • BLTE N/A
  • AMRX $719.66
  • Revenue Growth
  • BLTE N/A
  • AMRX 9.50
  • 52 Week Low
  • BLTE $49.00
  • AMRX $6.69
  • 52 Week High
  • BLTE $125.01
  • AMRX $12.12
  • Technical
  • Relative Strength Index (RSI)
  • BLTE 75.17
  • AMRX 62.32
  • Support Level
  • BLTE $108.75
  • AMRX $11.44
  • Resistance Level
  • BLTE $124.73
  • AMRX $11.91
  • Average True Range (ATR)
  • BLTE 7.56
  • AMRX 0.46
  • MACD
  • BLTE 0.44
  • AMRX 0.01
  • Stochastic Oscillator
  • BLTE 96.99
  • AMRX 75.59

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: